Prof Michael Hofman
Honorary Conjoint Professorial Fellow
The Sir Peter MacCallum Department of Oncology
416 Scholarly works
12 Projects
HIGHLIGHTS
2027
Research grants (ARC, NHMRC, MRFF)
Improving Prostate Cancer Outcomes by Integrating Novel Imaging and Targeted Therapy (Theranostics) for Personalised Medicine
2026
Journal article
Emerging role of functional imaging in renal cell carcinoma: from morphology to molecular phenotyping with PET/computed tomography
DOI: 10.1097/CCO.00000000000012272026
Journal article
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial.
DOI: 10.1038/s43018-026-01140-32022
Research grants (ARC, NHMRC, MRFF)
Personalised Medicine to Improve Outcomes for Men With Prostate Cancer Through Seamless Integration of Novel Imaging and Targeted Therapy (Theranostics)
2019
Research Grant
Up-Front Psma Alliance: Using Theranostics Early to Eradicate Prostate Cancer and Developing Novel Startegies for Psma-Negative Disease
2018
Journal article
Cold kit for prostate-Specific membrane antigen (PSMA) PET imaging: Phase 1 study of 68Ga-Tris (Hydroxypyridinone)-PSMA PET/CT in patients with prostate cancer
DOI: 10.2967/jnumed.117.1995542017
Journal article
Prostate-specific membrane antigen ligands for imaging and therapy
DOI: 10.2967/jnumed.116.186767
RECENT SCHOLARLY WORKS
2026
Journal article
Assoziation zwischen PRIMARY-Score und Gesamtüberleben bei der Stadieneinteilung mittels PSMA-PET bei Patienten mit neu diagnostiziertem Prostatakrebs: Ergebnisse des internationalen, multizentrischen PROMISE-Registers
DOI: 10.1055/s-0046-18181822026
Journal article
Neue Risikogruppen für Prostatakrebs anhand der PSMA-PET (PPP3)
DOI: 10.1055/s-0046-18182082026
Journal article
[177Lu]Lu-PSMA-617 in combination with pembrolizumab for treatment of metastatic castration resistant prostate cancer (PRINCE): a single-arm, phase 1b/2 study
DOI: 10.1016/S1470-2045(26)00017-32026
Journal article
Impact of peri-transplant consolidative radiotherapy in patients with relapsed or refractory classical Hodgkin lymphoma.
DOI: 10.1080/10428194.2026.26311022026
Journal article
New prostate cancer risk groups by PSMA-PET (PPP3): an international, retrospective, registry-based cohort study
DOI: 10.1016/S1470-2045(26)00016-12026
Journal article
177Lu-PSMA-617 SPECT/CT for Early Prediction of Overall Survival in Participants with Metastatic Castration-Resistant Prostate Cancer.
DOI: 10.1148/radiol.2526722026
Journal article
P0350 Biochemical recurrence and safety in patients with high-risk localised prostate cancer treated with [177Lu] Lu-PSMA-617 prior to prostatectomy: Follow-up of the LuTectomy trial
DOI: 10.1016/s0302-2838(26)01246-72026
Journal article
P0926 Confirmed prognostic value of PROMISE and PRIMARY at initial PSMA-PET: Preliminary findings from an international, multicentre registry
DOI: 10.1016/s0302-2838(26)01781-1